Commonwealth Equity Services LLC increased its stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get Rating) by 20.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,856 shares of the company’s stock after purchasing an additional 989 shares during the period. Commonwealth Equity Services LLC’s holdings in Biohaven Pharmaceutical were worth $807,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in BHVN. National Bank of Canada FI bought a new stake in shares of Biohaven Pharmaceutical in the 4th quarter worth approximately $28,000. Harbor Investment Advisory LLC increased its position in Biohaven Pharmaceutical by 25.4% in the 4th quarter. Harbor Investment Advisory LLC now owns 587 shares of the company’s stock valued at $81,000 after acquiring an additional 119 shares during the period. Montag A & Associates Inc. acquired a new stake in Biohaven Pharmaceutical in the 3rd quarter valued at approximately $96,000. PNC Financial Services Group Inc. increased its position in Biohaven Pharmaceutical by 9.8% in the 3rd quarter. PNC Financial Services Group Inc. now owns 808 shares of the company’s stock valued at $112,000 after acquiring an additional 72 shares during the period. Finally, Lindbrook Capital LLC acquired a new stake in Biohaven Pharmaceutical in the 4th quarter valued at approximately $113,000. 91.73% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE BHVN opened at $106.59 on Friday. The stock has a market capitalization of $7.52 billion, a price-to-earnings ratio of -8.15 and a beta of 1.06. The stock’s fifty day simple moving average is $119.76 and its 200 day simple moving average is $124.19. Biohaven Pharmaceutical Holding Company Ltd. has a 52-week low of $65.24 and a 52-week high of $151.51.
Several analysts recently commented on BHVN shares. Mizuho raised their target price on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the company a “buy” rating in a research report on Thursday, March 3rd. Morgan Stanley lowered their target price on Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. HC Wainwright reiterated a “buy” rating and set a $160.00 price target on shares of Biohaven Pharmaceutical in a research report on Friday, January 7th. Finally, UBS Group lifted their price target on Biohaven Pharmaceutical from $150.00 to $160.00 in a research report on Tuesday, January 4th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $148.27.
Biohaven Pharmaceutical Profile (Get Rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
- Get a free copy of the StockNews.com research report on Biohaven Pharmaceutical (BHVN)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.